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ABSTRACT
Ground based and inflight research has shown that humans,
under conditions of microgravity, sustain a loss of lean body
tissue (protein) and changes in several biological processes
including, reductions in red blood cell mass, and
neurotransmitters. The maintenance of muscle mass, the major
component of lean body mass, is required to meet the needs of
space station EVAs. Central to the biosynthesis of amino
acids, the building blocks of protein, is pyridoxine (vitamin
B-6). Muscle mass integrity requires the availability of
vitamin B-6 for protein metabolism and neurotransmitter
synthesis. Furthermore, the formation of red blood cells
require pyridoxine as a cofactor in the biosynthesis of
hemoglobin, a protein that carries oxygen to tissues. In its
active form, pyridoxal-5'-phosphate (PLP), vitamin B-6 serves
as a link between amino acid and carbohydrate metabolism
through intermediates of glycolysis and the tricarboxylic acid
cycle. In addition to its role in energy metabolism, PLP is
involved in the biosynthesis of hemoglobin and
neurotransmitter which are necessary for neurological
functions. Alterations in pyridoxine metabolism may affect
countermeasures designed to overcome some of these biochemical
changes.
The focus of this research is to determine the effects of
microgravity on the metabolic utilization of vitamin B-6,
integrating nutrition as an integral component of the
countermeasure (exercise) to maintain lean body mass and
muscle strength. The objectives are: I) to determine whether
microgravity effects the metabolic utilization of pyridoxine
and 2) to quantitate changes in B-6 vitamer distribution in
tissue and excreta relative to loss of lean body tissue. The
rational for this study encompasses the unique challenge to
control biochemical mechanisms effected during space travel
and the significance of pyridoxine to maintain and counter
muscle integrity for EVA activities. This experiment will
begin to elucidate the importance of biochemical interactions
between micronutrients and the homeostasis condition of
biological processes in the space environment.
To address this research topic a simulated microgravity
model has been developed. The experiment uses
radioisotopically labelled pyridoxine administered as an oral
dose to rats which are maintained by tail suspension to
simulate a microgravity environment. At the termination of
the study, liver, muscle, blood and urine are collected and
analyzed by reverse phase high pressure liquid chromatography
to determine the quantity and distribution of the B-6 vitamers
in tissue and excreta relative to lean body tissue loss.
Earlier studies, published by this investigator, have shown
that differences in vitamer distribution among samples from
experimental verses control subjects indicate changes in
metabolic utilization and storage of vitamin B-6.
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INTRODUCTION
Ground based and inflight research has shown that humans,
under conditions of microgravity, sustain a loss of lean body
tissue (protein) and changes in several biological processes
including, reductions in red blood cell mass, and
neurotransmitters. The maintenance of muscle mass, the major
component of lean body mass, is required to meet the needs of
space station EVAs. Central to the biosynthesis of amino
acids, the building blocks of protein, is pyridoxine (vitamin
B-6). Muscle mass integrity requires the availability of
vitamin B-6 for protein metabolism and neurotransmitter
synthesis. Furthermore, the formation of red blood cells
require pyridoxine as a cofactor in the biosynthesis of
hemoglobin, a protein that carries oxygen to tissues. In its
active form, pyridoxal-5'-phosphate (PLP), vitamin B-6 serves
as a link between amino acid and carbohydrate metabolism
through intermediates of glycolysis and the tricarboxylic acid
cycle. In addition to its role in energy metabolism, PLP is
involved in the biosynthesis of hemoglobin and
neurotransmitter which are necessary for neurological
functions. Alterations in pyridoxine metabolism may affect
countermeasures designed to overcome some of these biochemical
changes.
The focus of this research is to determine the effects of
microgravity on the metabolic utilization of vitamin B-6,
integrating nutrition as an integral component of the
countermeasure (exercise) to maintain lean body mass and
muscle strength. The objectives are: I) to determine whether
microgravity effects the metabolic utilization of pyridoxine
and 2) to quantitate changes in B-6 vitamer distribution in
tissue and excreta relative to loss of lean body tissue. The
rational for this study encompasses the unique challenge to
control biochemical mechanisms effected during space travel
and the significance of pyridoxine to maintain and counter
muscle integrity for EVA activities. This experiment will
begin to elucidate the importance of biochemical interactions
between micronutrients and the homeostasis condition of
biological processes in the space environment.
MATERIALS AND METHODS
To address this research topic a simulated microgravity
model has been developed. The experiment uses
radioisotopically labelled pyridoxine administered as an oral
dose to rats which are maintained by tail suspension to
simulate a microgravity environment. At the termination of
the study, liver, muscle, blood and urine are collected and
analyzed by reverse phase high pressure liquid chromatography
to determine the quantity and distribution of the B-6 vitamers
in tissue and excreta relative to lean body tissue loss.
Earlier studies, published by this investigator, have shown
that differences in vitamer distribution among samples from
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experimental verses control subjects indicate changes in
metabolic utilization and storage of vitamin B-6. The
chromatographic methodologies are being adapted to the HPLC
equipment at NASA. All of the above analytical methodologies
are being performed on a Hewlett-Packard HPLC with a loop
injection valve, a fluorometric detector, and an electronic
integrator. Excitation and emission wavelength are 295 nm and
405 nm respectively. Two mobile phases are being employed in
a gradient elution procedure using a Bondapak IP column.
Mobile phase A contains 0.033 mol/l phosphoric acid, and 8
mmol/l l-octanesulfonic acid, adjusted to pH 2.2. Mobile
phase B contains 0.033 mol/l phosphoric acid and 3.4 mol/l
acetonitrile, adjusted to pH 2.2 and no ion pairing reagent.
RESULTS
The results of this study will determine the effects of
microgravity on the metabolic utilization of pyridoxine and
establish the requirement for vitamin B-6 during space travel.
Alterations in pyridoxine metabolism may effect vitamin B-6
nutriture and the maintenance of lean body mass and muscle
strength, which are necessary components for EVA activities.
Statistical analysis on the distribution of vitamin B-6
vitamers between groups will be compared by the method of
least squares ANOVAusing general linear model procedures SAS,
following a logarithmic transformation of the data to
normalize the variance if necessary. Data will be reported as
least squares mean +/- the pooled standard error of the least
squares mean (SEM). Orthogonal contrasts will be made to
examine the linear and quadratic effects of different
independent variables on dependent variables.
DISCUSSION
The bioavailability of vitamin B-6 vitamers is a function
of their extent of absorption and metabolic conversion to
active coenzymatic forms. Pyridoxine that is absorbed from
the intestinal tract is concentrated initially in the liver
and is the sole source of plasma PLP. Thus, liver plays a
central role in the overall metabolism of vitamin B-6. The
major transformations in hepatic vitamin B-6 metabolism
involve phosphorylation catalyzed by pyridoxal kinase,
oxidation of PNP and PMP by pyridoxine (pyridoxamine) 5'-
phosphate oxidase, along with interconversion of PLP and PMP
through transamination reactions. The principal forms of
vitamin B-6 in liver are PLP and PMP. Pyridoxine 5'-phosphate
is usually present in only trace quantities because of its
rapid oxidation to PLP. The non-phosphorylated B-6 vitamers
constitute <10% of the total vitamin B-6 content in the liver.
The metabolic pathway for the degradation of PLP involves
enzymatic hydrolysis of the phosphate ester bond, and the
oxidation of pyridoxal to 4PA. As a terminal product of
vitamin B-6 metabolism, urinary 4PA reflects the in vivo
metabolic utillization of the vitamin.
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